

Obesity: The Disease and Its Management

Course Type: On-Demand Webcourse

Number of Credits: 1

Credit Type: CME/MOC/MIPS/AAFP

The educational program Obesity: The Disease and Its Management will provide clinicians with a greater understanding of the disease of obesity, including its etiology and physiologic effects, and management strategies, including the efficacy and safety of anti-obesity medications and how and when to incorporate them into individualized management plans.

PROGRAM OVERVIEW

Obesity is a growing public health crisis, with the obesity prevalence among US adults of 42.4%. The American Medical Association recognized obesity as a disease in 2013 and the Obesity Society and the Obesity Medicine Association have also issued statements defining obesity as a disease. However, most clinicians have received little or no education about obesity. Obesity management begins with lifestyle changes and counseling, with the addition of pharmacotherapy if needed, and if these measures are ineffective, referral to an obesity medicine specialist and possibly to a metabolic and bariatric surgeon. Unfortunately, many patients are not offered these recommended management strategies.

The educational program "Obesity: The Disease and Its Management" will provide clinicians with a greater understanding of the disease of obesity, including its etiology and physiologic effects, and management strategies, including the efficacy and safety of anti-obesity medications and how and when to incorporate them into individualized management plans.

PROVIDER

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Release Date: August 16, 2021 Expiration Date: August 16, 2022

"Obesity: The Disease and Its Management" click here....

<https://cme.rockpointe.com/obesity-the-disease-and-its-management/>

Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy

Course Type: On-Demand Webcourse

Number of Credits: 1

Credit Type: CME/AAFP/MOC/MIPS

The educational program Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy will familiarize primary care physicians with the pathophysiology of CVD in T2DM, results of cardiovascular outcomes trials of antihyperglycemics, and recommendations from several societies regarding the use of these agents in patients with T2DM who have or are at risk for CVD.

PROGRAM OVERVIEW

Approximately 13% of the US adult population has diabetes, with the majority (95%) having type 2 diabetes mellitus (T2DM). Cardiovascular disease (CVD) is the number one cause of death for patients with T2DM. The pathophysiology of T2DM contributes to atherogenesis and has a direct effect on the myocardium.

The cardiovascular effects of newer antihyperglycemic drugs have been studied in prospective cardiovascular outcomes trials, while information from older agents comes from observational studies and meta-analyses. These data led many societies to publish updated guidelines on the management of patients with T2DM with or at high risk for CVD, incorporating the cardiovascular effects of antihyperglycemic agents.

The educational program Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy will familiarize primary care physicians with the pathophysiology of CVD in T2DM, results of cardiovascular outcomes trials of antihyperglycemics, and recommendations from several societies regarding the use of these agents in patients with T2DM who have or are at risk for CVD.

PROVIDER

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Release Date: August 16, 2021 Expiration Date: August 16, 2022

"Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy" click here....

<https://cme.rockpointe.com/improving-cardiovascular-outcomes-in-t2dm-personalizing-antihyperglycemic-therapy>